PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

NIH, FDA Seek Broader Disclosure of Clinical Trial Results

A Tale of Two Pricing Schemes

CETA in the Balance

Business Models

Biosimilars Face Repercussions of Drug Pricing Debate

Concerns have emerged that continued growth in biosimilars could be limited by mounting pressure to push down on prescription drug outlays. Jill Wechsler reports.
... /Read more/

Read this Front & Center article to see how your Hub can be a Secret Weapon to improve Outcomes

Learn more

Pricing & Reimbursement

Combination Products High on Regulatory Radar Screen

The EpiPen eruption plus the emergence of more cutting-edge therapies with drug and biotech components has put combination products under the spotlight. Jill Wechsler reports.
... /Read more/

Opinion

Eight Characteristics of Blockbuster Teams

The secret sauce for creating blockbuster brands has always been – and always will be – consistently exceptional team execution. Andy Mehrotra offers the recipe.
... /Read more/

Executive Profile

Emerging Leaders 2016: Lessons from the Front Bench

Pharm Exec sits down with UBC President Patrick Lindsay to provide some real-world context around our 2016 feature profile of 16 Emerging Leaders in biopharma.
... /Read more/

Calendar

/ CDISC 2016 International Exchange /

/ HP PharmaCon /

/ 7th Hub and SPP Model Optimization /

Operations Management

Patient-Centered Strategies for Clinical Trials & Treatment

Pharm Exec and inVentiv Health convened a roundtable discussion at the 2016 ASCO meeting to review the use of patient-reported outcomes (PRO) in the clinical trial and commercialization space.
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com